Key result
Colchicine 0.5 mg/day cuts major events ~67% vs no colchicine.
Why the study?
Activated neutrophils in culprit plaques suggested that inhibiting neutrophil function with colchicine might reduce plaque instability and cardiovascular events in stable coronary disease.
Does colchicine 0.5 mg/day reduce the composite incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke in patients with stable coronary disease?
RCT (n=532)
observer-blinded endpoint
randomized
Does colchicine 0.5 mg/day reduce the composite incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke in patients with stable coronary disease?
Effect estimate: HR 0.33 (95% CI 0.18-0.59)
Absolute Event Rate: 5.3% vs 16%
p-value: p=<0.001
Low-dose colchicine (0.5 mg/day) added to standard medical therapy significantly reduces the risk of cardiovascular events in patients with stable coronary disease.
No takes yet. Share an insight, caveat, or question.
Supports adding low-dose colchicine in stable CAD; confirms benefit for secondary prevention of major CV events.
Nidorf et al. (2012) conducted an RCT in stable coronary disease (n=532). Colchicine vs. No colchicine was evaluated on composite incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke (HR 0.33, 95% CI 0.18-0.59, p=<0.001). Colchicine 0.5 mg/day reduced the composite of acute coronary syndrome, cardiac arrest, or ischemic stroke compared to no colchicine (HR 0.33; 95% CI 0.18-0.59; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: